Alan Dean
Senior Managing Partner
Alan Dean is a senior technology executive with over 30 years of experience in the technology development industry, and has been an advisor to, and board member of, numerous technology companies, past and present. Alan is the co-founder and senior managing partner of the Targeted Technology Fund I. Previously, Alan was Managing Partner, Fund Operations, for Greer Capital Advisors in Birmingham, Alabama, with two-dozen portfolio companies and approximately $70 million under direct management.
Prior to joining Greer Capital Advisors in 2006, Alan was the Director of the Office of Technology Ventures at the University of Texas Health Science Center (UTHSCSA), resulting in a more than doubling of assessed inventions, growth in the revenue-generating intellectual property portfolio to over 100 active licenses, and the office’s first ever profit from licensing revenues. One licensing example, Clofarabine (Clolar®), was acquired by ILEX Oncology and was FDA approved in 2004, the year ILEX was acquired by Genzyme Corporation for $1B.
Alan’s experience includes the formation of Southern Research Technologies (“SRT”) in the late 1980’s, an independent, for profit technology spin-off from the Southern Research Institute in Birmingham, Alabama, and the formation and subsequent spin-off of a biodegradable polymers and drug-delivery technology business, Southern Bio Systems, Inc. (“SBS”). As the co-founder and COO of SBS, Alan was responsible for the buyout and integration of Birmingham Polymers, Inc., a Bristol-Myers-Squibb affiliate. SBS was subsequently acquired by Durect Corp. of California in 2001 in a transaction valued at $35 million.
Alan earned his MBA from the University of Alabama in Birmingham and his BS in Chemistry from the University of Alabama.
